Morphogen-IX

Morphogen-IX operates as a preclinical biotechnology firm, established as a spin-out from the University of Cambridge in 2015. The company was founded by Professor Nick Morrell, alongside Dr. Wei Li and Dr. Paul Upton, based on 15 years of research conducted in Professor Morrell's lab. Professor Morrell, who later also served as CEO, is the British Heart Foundation Professor of Cardiopulmonary Medicine at the University of Cambridge and has over two decades of experience in the field of pulmonary arterial hypertension (PAH), lending significant domain expertise to the company's mission.

The company's core focus is the development of therapies for pulmonary arterial hypertension, a rare and life-threatening condition characterized by the narrowing of blood vessels in the lungs, which leads to heart failure. Morphogen-IX's business model is centered on the research and development of a disease-modifying drug, targeting the fundamental causes of PAH rather than merely alleviating symptoms. The primary client base for its eventual product consists of patients suffering from this debilitating disease. The company's main therapeutic candidate, MGX292, is a protein-engineered variant of Bone Morphogenetic Protein 9 (BMP9). This engineered protein is designed to restore the protective function of the native BMP9 protein for lung blood vessels, a function that is often reduced in patients due to genetic causes, without inducing the bone-forming properties of the natural protein.

Significant milestones for Morphogen-IX include securing £1.5 million in seed funding in 2016, led by Index Ventures, Cambridge Innovation Capital, and Cambridge Enterprise. This was followed by a substantial £18.4 million Series B financing round in December 2018, led by Medicxi, to advance MGX292 through preclinical development and into clinical trials. In a strategic move in February 2021, Morphogen-IX was acquired by Centessa Pharmaceuticals through a share exchange, becoming one of 10 biotech companies merged to form the new entity. This acquisition provided the financial backing and scaled R&D model necessary to further the development of its promising pipeline.

Keywords: pulmonary arterial hypertension, bone morphogenetic proteins, BMP9, University of Cambridge spin-out, Nick Morrell, drug development, preclinical biotechnology, MGX292, Centessa Pharmaceuticals, orphan diseases, vascular disease therapy, protein engineering, life sciences, drug discovery, heart failure treatment, genetic medicine, Cambridge biotech, biopharmaceutical, therapeutic development, endothelial protection